Drug discovery startup GTN lands £2.1m Seed from Octopus Ventures

May 4, 2018 · uktech.news

Noornew2 898x505

London-based startup GTN has raised £2.1m in Seed funding in a round led by Octopus Ventures to transform drug discovery.

Pentech and existing investor Entrepreneur First also contributed to the round, which will be used to build on GTN’s drug discovery technology.

On average, bringing a new drug to the market costs $2.9bn and takes 15 years, with a high chance of failure; plus an expected 50% drop in R&D output every nine years.

GTN, a female-led company, has developed a technology called Generative Tensorial Networks. It combines and builds upon techniques from machine learning and quantum physics to simulate, filter and discover new molecules. The company says this will help bring efficiencies to the drug development cycle, discovering much-needed medicines for patients with cancer, autoimmune and infectious diseases.

Read Complete Article

RT @Startup_van: Is this the best way to build your @instagram following? We have @_liamdoolan from https://t.co/RV7OJqKhuK join us to chat…

During today’s Crossrail 2 all-party parliamentary group meeting, I spoke to politicians from all sides to discuss… https://t.co/nRRlWdDzA6

RT @BeMyAppUK: London Tech Week is upon us! There are so many ways to get involved this year. If you are part of the London #tech #ecosyste…

Elon Musk hits out at 'holier-than-thou hypocrisy' and lies of media https://t.co/CJb0ejyCu5 via @telegraphtech

Square launches its Square Stand payments system in the UK https://t.co/38zbGQe8OO